home / stock / ipsey / ipsey quote
Last: | $29.79 |
---|---|
Change Percent: | -0.26% |
Open: | $30.35 |
Close: | $29.79 |
High: | $30.35 |
Low: | $29.79 |
Volume: | 680 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$29.79 | $30.35 | $29.79 | $30.35 | $29.79 | 680 | 04-23-2024 |
$30.27 | $30.27 | $30.27 | $30.27 | $30.27 | 494 | 04-22-2024 |
$28.755 | $28.755 | $28.755 | $28.755 | $28.755 | 1,330 | 04-19-2024 |
$28.72 | $28.72 | $28.72 | $28.72 | $28.72 | 491 | 04-18-2024 |
$28.6225 | $28.6225 | $28.6225 | $28.6225 | $28.6225 | 491 | 04-17-2024 |
$28.615 | $28.615 | $28.615 | $28.615 | $28.615 | 556 | 04-16-2024 |
$29.18 | $0 | $29.18 | $0 | $0 | 229 | 04-15-2024 |
$29.18 | $0 | $29.18 | $0 | $0 | 240 | 04-12-2024 |
$29.18 | $29.18 | $29.18 | $29.18 | $29.18 | 2,548 | 04-11-2024 |
$29.8 | $0 | $29.8 | $0 | $0 | 300 | 04-10-2024 |
$29.8 | $29.8 | $29.8 | $29.8 | $29.8 | 647 | 04-09-2024 |
$29.76 | $29.76 | $29.76 | $29.76 | $29.76 | 745 | 04-08-2024 |
$29.45 | $28.9325 | $29.45 | $29.45 | $28.9325 | 771 | 04-05-2024 |
$29.69 | $29.54 | $29.69 | $29.69 | $29.54 | 1,110 | 04-04-2024 |
$28.53 | $28.53 | $28.53 | $28.53 | $28.53 | 354 | 04-03-2024 |
$28.66 | $28.66 | $28.66 | $28.66 | $28.66 | 31,056 | 04-02-2024 |
$30.34 | $30.34 | $30.34 | $30.34 | $30.34 | 549 | 04-01-2024 |
$29.88 | $29.8 | $29.88 | $29.95 | $29.8 | 520 | 03-29-2024 |
$29.88 | $29.8 | $29.88 | $29.95 | $29.8 | 520 | 03-28-2024 |
$29.41 | $29.535 | $29.41 | $29.535 | $29.41 | 674 | 03-27-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...